Current consensus guidelines of the Brazilian Group of Gastrointestinal Tumours recommend evaluating HER2 status, MMR/MSI, PD-L1, and neurotrophic tyrosine receptor kinase in GEJC biopsies [31]. Here, ERBB2 is linked to digestive system neoplasm.